Viatris lawsuit is the one to watch 20312033: Most analysts' baseline forecast for final FDA approval and US market launch, assuming patents run their course 20332036: More conservative estimates accounting for remaining IP layers What could change this timeline: Further successful patent challenges by generic manufacturers Congressional or executive action to accelerate generic biologics access Expanded FDA streamlining of the biosimilar approval pathway For now, the cost relief available globally in 2026 will not reach US patients through the generic or biosimilar route
Raphael Cuomo, PhD, MPH, of the University of California San Diego School of Medicine, and colleagues looked at the association between use of GLP-1 drugs and five-year mortality among patients with primary colon cancer (cancer that first arises in the colon), taking into account body mass index (BMI)
This is also the case for plasma insulin levels in humans where a mixed liquid meal is a stronger stimulus than oral glucose alone
Thats why GLP 1 Support is third-party tested and made in a cGMP- and SQF-certified facility to ensure purity and potency
Whoever can re-engineer the center-store assortment and the QSR menu around that basket captures share that the incumbents are bleeding on the legacy mix
This dual-action approach is why Tirzepatide often leads to better weight loss results, with fewer symptoms